Open database of authors and journals




Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.

PLoS ONE, 2022, 17, e0261336

Similar Articles

Quick Tips
This is an overview of where and by who this paper has been cited.
Help Us
Non-profit projects normally ask for donations. We don't. We will survive one way or another. If you wish to help us, please spread the word to let more people use this service.

It is delightful to see our efforts are useful to a broad range of researchers.
EXALY
Profiles
Fields
Search Engines
Tools